Anpheros Search · Treatment

Osilodrostat

Also known as: Isturisa

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

Osilodrostat is a cortisol synthesis inhibitor that has an approved use for the treatment of Cushing syndrome. In the European Union, it is indicated for the treatment of endogenous Cushing’s syndrome in adults. In the United States, it is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

From: Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency. · Source: European Medicines Agency (EMA), Isturisa — EPAR, 12/12/2024. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm
2286252 osilodrostat
EMA
EMEA/H/C/004821

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Isturisa

Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.

Source: European Medicines Agency (EMA), Isturisa — EPAR, 12/12/2024. © European Medicines Agency.

Document date: 12/12/2024 · Official document →

FDA (USA) Isturisa

1 INDICATIONS AND USAGE ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative ( 1 )

Data provided by the U.S. Food and Drug Administration.

Document date: 20251118 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Osilodrostat approved for in the European Union?

Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults. (Source: European Medicines Agency (EMA), Isturisa — EPAR, 12/12/2024. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • Data provided by the U.S. Food and Drug Administration.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Isturisa — EPAR, 12/12/2024. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →